Drug Trial Radar · NCT06785727
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
Last checked: Nov 19, 2026Latest source record: Jan 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
612
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Dec 1, 2028
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- Prof. dr. Nathalie van der VeldeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- VU University of Amsterdam
- First posted
- Jan 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 70 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST - RCT, the investigators will assess the impact of starting versus not starting a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and Major Adverse Cardiovascular Events (MACE) free survival during a two-year follow-up period.
Conditions
- Ischemic Stroke
- Transient Ischemic Attack
Interventions
Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)Drug
The intervention group receives statin treatment following the current "Herseninfarct en Hersenbloeding" guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Health-Related Quality of Life (HrQoL)Time frame: 3, 6, 12, 18, 24 (and 36) months.
- Major Adverse Cardiovascular Events (MACE) free survivalTime frame: 3, 6, 12, 18, 24 (and 36) months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.